Reporting of sex- and age-specific outcomes for antibody drug conjugate-induced nausea and vomiting in patients with cancer

Purpose To evaluate how often studies of antibody drug conjugate-induced nausea and vomiting (ADCINV) report demographic characteristics and demographic-specific toxicity outcomes. Methods We conducted a secondary analysis of 202 studies included in a systematic review of ADCINV. We summarized study country and income setting, age and sex reporting, and whether nausea and vomiting outcomes were reported by age, sex, or country/region. Results Most studies were conducted in high-income settings (144/202, 71.3%). One hundred forty-eight studies (73.3%) reported at least one age summary, although only 22 (10.9%) reported an older-adult proportion. Overall, 123 studies (60.9%) reported the percentage of female participants. No study reported nausea or vomiting outcomes stratified by age, sex, or country/region. Conclusion ADC studies frequently report overall nausea and vomiting but do not provide the demographic-specific outcomes needed to evaluate differential risk. Standardized reporting by age, sex, and geographic setting is needed in future trials and real-world studies.

Authors

Institutions

Publication Details

Journal
Supportive Care in Cancer
Published
2026-11-19
DOI
https://doi.org/10.1007/s00520-026-11508-x
Primary Topic
Nausea and vomiting management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Reporting of sex- and age-specific outcomes for antibody drug conjugate-induced nausea and vomiting in patients with cancer

Ronald Chow, Jennifer Leigh, Lawson Eng, Maaz Syed et al.
Supportive Care in Cancer
Nausea and vomiting management
article

Reporting of sex- and age-specific outcomes for antibody drug conjugate-induced nausea and vomiting in patients with cancer

Ronald Chow, Jennifer Leigh, Lawson Eng, Maaz Syed, Sumeet Talwar, Samy Kannout, Daniel Zhang, Yigeng Tan, Manu Beniwal
article en

Abstract

Purpose To evaluate how often studies of antibody drug conjugate-induced nausea and vomiting (ADCINV) report demographic characteristics and demographic-specific toxicity outcomes. Methods We conducted a secondary analysis of 202 studies included in a systematic review of ADCINV. We summarized study country and income setting, age and sex reporting, and whether nausea and vomiting outcomes were reported by age, sex, or country/region. Results Most studies were conducted in high-income settings (144/202, 71.3%). One hundred forty-eight studies (73.3%) reported at least one age summary, although only 22 (10.9%) reported an older-adult proportion. Overall, 123 studies (60.9%) reported the percentage of female participants. No study reported nausea or vomiting outcomes stratified by age, sex, or country/region. Conclusion ADC studies frequently report overall nausea and vomiting but do not provide the demographic-specific outcomes needed to evaluate differential risk. Standardized reporting by age, sex, and geographic setting is needed in future trials and real-world studies.

Supportive Care in CancerVol. 34(12)
Alberta Health Services (CA), Sunnybrook Health Science Centre (CA), University Health Network (CA), University of Illinois Urbana-Champaign (US), University of Toronto (CA), Princess Margaret Cancer Centre (CA), University of Oxford (GB), Sunnybrook Hospital (CA), Odette Cancer Centre (CA)
Nausea and vomiting management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon